The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this report, we present a comprehensive market forecast for the current and emerging chimeric antigen receptor (CAR) T-cell therapies across oncology indications. We also provide key opinion leaders’(KOLs’) insights regarding the current and emerging CAR T-cell treatment landscape.
United States, EU5, Japan
14 country-specific interviews with thought-leading hematologist-oncologists and trial investigators.
Drug-treated patient populations for acute lymphoblastic leukemia, relevant non-Hodgkin’s lymphoma subpopulations, chronic lymphocytic leukemia, and multiple myeloma, by country and line of therapy.
Ten-year, annualized, drug-level sales and patient shares for CAR T-cell therapies through 2027, segmented by indication and patient subpopulation.
The CAR T-Cell Therapy Special Topics Report is a unique product offering a consolidated full market forecast of the CAR T-cell landscape in oncology through 2027. This forecast is supplemented with interviews conducted with KOLs from all seven major pharmaceutical markets under study.